 LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 PRNewswire - Liminal BioSciences Inc. NASDAQ: LMNL Liminal BioSciences or the Company, announced today that its subsidiary Prometic Biotherapeutics Inc. PBT has closed on the sale of its Priority Review Voucher PRV for USD 105 million. 